Premier Biotech Broadens Product Portfolio With NexScreen and TransMed Acquisitions
Align Capital Partners’ (“ACP”) drug and alcohol testing solutions provider, Premier Biotech (“Premier” or the “Company”), announced the acquisitions of NexScreen and TransMed. These strategic acquisitions expand Premier’s global footprint and online presence, enhance the Company’s product portfolio and deepen customer relationships across healthcare, government and workplace markets.
NexScreen provides point-of-care diagnostic testing solutions to customers across the United States, Australia and New Zealand. TransMed offers a broad catalog of drug testing products and laboratory supplies to +1,000 direct customer accounts, supported by its e-commerce platform and an extensive international network of manufacturers, suppliers and resellers. Together, these acquisitions significantly strengthen Premier’s ability to deliver a comprehensive, end-to-end suite of solutions to its growing global customer base.
“Partnering with Premier Biotech is an exciting next step for NexScreen, and we look forward to bringing Premier’s full solution set to our customers,” said John Debrovner, CEO of NexScreen. “Premier’s robust portfolio is unmatched, and we are thrilled to offer their oral fluid, laboratory and technology solutions to our markets.”
